- Home
- ALMS
ALMS
ALUMIS INC
as 02-21-2025 4:00pm EST
Stocks
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
Upcoming Earnings Alert:
Get ready for potential market movements as ALUMIS INC ALMS prepares to release earnings report on 28 Feb 2025.
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 469.0M | IPO Year: | 2024 |
| Target Price: | $28.83 | AVG Volume (30 days): | 263.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -15.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.74 - $13.53 | Next Earning Date: | 02-28-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ALUMIS INC News
ALMS Breaking Stock News: Dive into ALMS Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
GlobeNewswire
11 days ago
Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
MT Newswires
12 days ago
Oppenheimer Adjusts Price Target on Alumis to $26 From $32, Keeps Outperform Rating
Pharmaceutical Technology
15 days ago
Alumis and Acelyrin sign merger agreement
Simply Wall St.
15 days ago
We're Keeping An Eye On Alumis' (NASDAQ:ALMS) Cash Burn Rate
BioPharma Dive
15 days ago
Immune drugmakers Alumis and Acelyrin to merge
GlobeNewswire
15 days ago
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
GlobeNewswire
25 days ago
Alumis Strengthens Leadership Team with Key Appointments
Compare ALMS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALMS ALUMIS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.